Application of dll4 cytokine in preparation of medicament for treating fulminant hepatic failure

A technology for liver failure and cytokines, applied in the fields of clinical medicine, molecular medicine and regenerative medicine, can solve the problems of shortage of donor livers and death of patients, and reduce the level of bilirubin, promote the formation of new blood vessels, and reduce transaminase. Effect

Active Publication Date: 2018-08-31
ZHEJIANG UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But due to a severe shortage of donor livers, a large number of patients died while waiting for a liver transplant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dll4 cytokine in preparation of medicament for treating fulminant hepatic failure
  • Application of dll4 cytokine in preparation of medicament for treating fulminant hepatic failure
  • Application of dll4 cytokine in preparation of medicament for treating fulminant hepatic failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1: Injection containing DLL4 cytokines treats a large animal (young pig) model of fulminant hepatic failure

[0044] Animal model: 30 male Chinese young pigs (8-10 kg) were randomly divided into two groups, 15 in each group. Each jugular vein injection of D-gal 1.5g / kg, resulting in fulminant hepatic failure model.

[0045] Test group: multiple intravenous injections of DLL4 injection at fixed time points after D-gal injection, dose: 10ml / kg, twice a day.

[0046] Control group: inject the same amount of normal saline without DLL4.

[0047] Neither the control group nor the experimental group received other drug treatment.

[0048] figure 1 It is a schematic diagram of the survival time curves of the young pigs of the experimental group and the control group, showing the survival rate of the young pigs of the experimental group and the control group. The results showed that the 3-day survival rate of young pigs in the treatment group containing DLL4 cytokine...

Embodiment 2

[0049] Example 2: The small animal (rat) model of fulminant hepatic failure treated by lyophilized powder injection containing DLL4 cytokine

[0050] Animal model: 100 male rats (200-250 g) were randomly divided into two groups, 50 in each group. Each rat was intraperitoneally injected with D-gal 1.5g / kg to make a model of fulminant hepatic failure. DLL4 lyophilized powder and water for injection are prepared into a suspension.

[0051] Experimental group: 4 ml of DLL4 lyophilized powder suspension was injected intraperitoneally at a fixed time point after D-gal injection, twice a day.

[0052] Control group: inject the same amount of normal saline without DLL4.

[0053] Both the control group and the experimental group received no other drug treatment.

[0054] figure 2 Schematic diagram of the survival time curves of rats in the experimental group and the control group, figure 2The survival rates of the rats in the experimental group and the control group were shown: ...

Embodiment 3

[0055] Example 3: The suspension containing DLL4 cytokines treats a rabbit model of fulminant hepatic failure

[0056] Animal model: 40 adult male rabbits (2000-2500 g) were randomly divided into two groups, 20 in each group. Each rabbit was intramuscularly injected with D-gal 1.5g / kg to make a model of fulminant hepatic failure.

[0057] Test group: Intramuscular injection of DLL4 suspension 20ml at a fixed time point after D-gal injection, twice a day.

[0058] Control group: inject the same amount of normal saline without DLL4.

[0059] Both the control group and the experimental group received no other drug treatment.

[0060] image 3 It is a schematic diagram of the survival time curves of rabbits in the experimental group and the control group, image 3 The survival rate of the rabbits in the experimental group and the control group is expressed: the results show that the survival rate of the rabbits in the DLL4 treatment group is 95% at 3 days, 90% at 7 days, and 9...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a use of the DLL4 cell factor in preparing a drug for treating fulminant hepatic failure. DLL4 can not only significantly improve the survival rate in a treatment of fulminant hepatic failure, but also significantly improve the survival rate by improving prognosis of a treatment of a severe or terminal stage hepatic disease having a similar underlying cause, disease progression and prognosis.

Description

technical field [0001] The invention belongs to the fields of clinical medicine, molecular medicine and regenerative medicine, and specifically relates to a new technology for treating fulminant liver failure with DLL4 cytokine series drugs. Background technique [0002] Fulminant hepatic failure is a kind of disease caused by extensive necrosis of the liver caused by various reasons. Except for orthotopic liver transplantation, there is currently no specific treatment. However, due to the severe shortage of donor livers, a large number of patients died while waiting for liver transplantation. If we can find one or more cytokines that can not only inhibit liver necrosis, but also quickly induce host liver tissue regeneration and long-term function, and avoid potential side effects, it will be of great significance for the treatment of fulminant liver failure caused by various reasons. extremely important. DLL4 cytokine is a type I transmembrane protein located on the cell...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/19A61P1/16
CPCA61K38/19
Inventor 李君李兰娟陈新李江
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap